Charnwood Campus Science, Innovation and Technology Park
Former Astra Zeneca Charnwood Research and Development centre. Now a leading Science and Innovation Campus focusing on the biopharmaceutical sector. The first in the UK Life Sciences Opportunity Zone and a successful Enterprise Zone.
Ideally situated on the outskirts of Loughborough, in the heart of the UK, the Campus benefits from excellent transport links.
To become a leading next-generation life sciences cluster in the UK, driving innovation, growth and improving healthcare for all. Built on 3 sustainability pillars underpinned by adherence to best industry practices and stringent regulatory cGMP/cGLP/cGDP requirements.
Environmental considerations for the wellbeing of future generations
Wellbeing of the Charnwood Campus, Loughborough and wider community
Economic sustainability of the Campus, growth for local supply chain organisations, prosperity for the region and wider area
Dr Lucille Alexander
Gosia Khrais, BSc (Hons) PGDip CQI
Charnwood Campus developed a number of strategic partnerships with a range of local, regional and national governmental agencies to help realise its ambition to become a leading driver of change within the life sciences sector.
Since its inception, Charnwood Campus has safeguarded or created over 800 science jobs in the region. Charnwood Campus was formed in 2014 and has worked relentlessly to regenerate the derelict site vacated by AstraZeneca in 2011 into a sustainable science park. The Campus has created a successful formula to redevelop the site, building by building, by following suggestions included in the Transforming UK Life Science Sites - Toolkit for Action launched by Rt Hon George Freeman on Charnwood Campus in March 2016.
Charnwood Campus managed to attract and/or retain within the region a number of blue-chip organisations and several high growth SME’s have relocated to Charnwood Campus: including Almac Group’s drug development services, research, and manufacturing facility, 3M’s Health Care business operations, Kindeva Drug Delivery System’s manufacturing and R&D and Charnwood Molecular recently expanded medicinal chemistry and process research teams and related drug discovery service lines and will be relocating with recently acquired biology services company Aurelia Bioscience.
We have now 800+ scientists on-site and the Campus is helping to drive the flourishing life science cluster in the region, through the Business support programme and Talent and Skills Institute.
Leading UK pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, Charnwood Molecular, has joined Charnwood Campus and expanded its operations in a deal expected to support the growth of its contract research services. Charnwood Molecular’s ambitious growth plans now see the company becoming the sole occupier of a substantial three-storey, state-of-the-art laboratory facility at Charnwood Campus.
Launched in October 2021 and endorsed by Rt. Hon George Freeman Charnwood Campus Life Sciences Talent and Skills Institute is an exemplar platform where industry and academia work together to solve short and long term skills challenges by creating a clear path from study to the workplace, circular development and upskilling employees.
Global contract development and manufacturing organisation (CDMO) Kindeva Drug Delivery has expanded its operations at Charnwood Campus, in a deal to support Kindeva’s continued growth in the UK. The US-headquartered company has taken over a state-of-the-art research and development facility at Charnwood Campus, and a further 20,000 square feet of office space at the site.
COVID-19 testing ‘Lighthouse Lab’ opens at Charnwood Campus. A new ‘Lighthouse Lab’ facility will be established in Leicestershire to increase the UK’s COVID-19 testing capacity, in an investment creating 400 jobs. The UK Department of Health and Social Care’s Lighthouse Lab at Charnwood Campus in Loughborough is a partnership with global diagnostics company PerkinElmer.
3M Drug Delivery Systems Relocates U.K. R&D to New, State-Of-The-Art Facility. 3M Drug Delivery Systems (DDS) U.K. organization is bringing its teams under one roof, with 120 research and development employees moving to the DDS R&D Inhalation Centre of Excellence, Building 39.
The science-based technology company 3M has begun the next era in its long relationship with Loughborough after the official opening of new offices on Charnwood Campus. Some 170 employees have relocated to Building 47 on the science, technology and enterprise park from 3M’s previous site at Morley Street, where it had been based since the early 1950s. Their new 3,400m2 home has office space arranged over three floors within half a mile of the company’s Derby Road manufacturing and distribution site.
Charnwood Campus is endorsed as the first UK Life Science Opportunity Zone (LSOZ) and therefore the site benefits from engagement with government ministers and officials from the Department for International Trade and the Office for Life Science as part of the Life Sciences Industrial Strategy.
Life Science’s Minister George Freeman MP visited Charnwood Campus in Loughborough to meet the team responsible for the transformation of the world-class pharmaceutical site, and to discuss its potential role in strengthening the local economy. His visit coincided with the publication of a new report, ‘Transforming Life Sciences Sites – a toolkit for action’ by a group of senior stakeholders from across the UK¹.
Almac Group expands its UK operations to Loughborough. Almac Group provides integrated drug development services, research and manufacturing to about 600 clients worldwide within diagnostics, clinical services, clinical technologies and pharmaceutical sectors.
First tenants on the campus
ARM specializes in developing cutting-edge, next-generation camera and display subsystems, bringing deep knowledge of human visual processing to create the best possible image quality and new user experiences.
Close cooperation with Charnwood Council, Leicester City Council, Medilink East Midlands, LLEP, Business Innovation & Skills, and Office for Life Sciences resulted in firming up Charnwood Campus Investment and Implementation Strategy.
Fisons bought by Astra. Merged with Zeneca of Sweden to form Astrazeneca.
Expansion with the building of the Biology and Chemistry facilities.
Modernisation and expansion programme with the building of the pharmacology building.
Construction of new research and manufacturing buildings was completed at Bakewell Road. The discovery and development of a second inhaled compound was subsequently marketed as TILADE. Other projects were started with significant compounds being discovered and also the discovery of DOPACARD
The significant discovery of INTAL, a fundamentally new approach to asthma therapy, was well under way during the 1950s and was marketed in 1968.
Fisons (which dated back to the 1700s). Fisons bought a part share in the then Loughborough-based company Genatosan, manufacturers of Sanatogen nerve tonic.